Navigation Links
OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
Date:3/4/2009

BOTHELL, WA and VANCOUVER, March 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and fiscal year 2008 financial results will be released on Wednesday, March 11, 2009, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Management will discuss the company's financial results and provide a 2009 corporate outlook.

A live webcast and slide presentation will be available through the Events and Presentations Web page found in the Investors Relations section of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-874-1569 (U.S. & Canada) or 719-325-4767 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... Research and Markets has announced ... 2014-2018" report to their offering.  ... the in vitro growth of plant or animal cells ... biopharmaceutical production. Cell culture is a crucial step in ... cell culture consumables are necessary for the in vitro ...
(Date:7/24/2014)... San Francisco, CA (PRWEB) July 24, 2014 ... Wednesday to be semi-finalists in Livestrong’s Big C Competition. ... Decisive Health are each headed to the semi-final round. ... in Livestrong’s exclusive three-month accelerator program, complete with mentoring ... country. , As part of the angelMD commitment ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... ) today announced that Dan Maher , Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in ... ... ... ...
... ... pressure switches and pressure transmitters moves to Hatfield, Pa. , ... Hatfield, PA (Vocus) March 17, 2010 -- ... a new production line for the recently acquired pressure gauge product family at its ...
... ... generation business intelligence software, today announced the availability of Centrifuge 1.8, the latest version ... ... Centrifuge Systems, Inc. , a leading provider of next generation business intelligence software, ...
Cached Biology Technology:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2BioMarin to Present at the Barclays Capital Global Healthcare Conference 3Brooks Instrument Opens Pressure Gauge Production Line 2Brooks Instrument Opens Pressure Gauge Production Line 3Centrifuge Releases New Data Visualization Software 2Centrifuge Releases New Data Visualization Software 3
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... of Adelaide has opened the way for the development of ... In Australia, annual barley production is second only to wheat ... of the most important diseases of barley. , Senior Research ... of special growths on the cell walls of barley plants ... , The research, by the ARC Centre of Excellence in ...
(Date:7/25/2014)... a complex congenital central nervous system disease that ... neural tubes during the embryonic phase. Many patients ... incontinence and neurocognitive retardation. Such problems decrease the ... Researchers at Ankara Physical Medicine and Rehabilitation Education ... in children with SB, using the Pediatric Evaluation ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... formation of the centromere, a key cellular structure in powering ... earned him a paper in Nature Cell Biology ... year, for a maximum of five years. Lars Jansen ... in Portugal, last year to head the Epigenetic Mechanisms group. ...
... repairing DNA strands damaged by oxidation leads to several ... contributes to the development of cancer. That,s the conclusion ... by researchers at the National Institute of Standards and ... the New York University School of Medicine (NYUSM). ...
... CHICAGO The American Dietetic Association has released an ... diets, if well-planned, are healthful and nutritious for adults, ... treat chronic diseases including heart disease, cancer, obesity and ... of the Journal of the American Dietetic Association ...
Cached Biology News:Double success for Instituto Gulbenkian de Ciencia scientists working on chromosome segregation 2Genetically engineered mice yield clues to 'knocking out' cancer 2ADA releases updated position paper on vegetarian diets 2